NCT07713056 Clinical Characteristics of Pigmentary Glaucoma and Efficacy Analysis of Ab-interno 120° Trabeculotomy
| NCT ID | NCT07713056 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Zhongnan Hospital |
| Condition | Pigmentary Glaucoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 11 participants |
| Start Date | 2026-04-01 |
| Primary Completion | 2026-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 11 participants in total. It began in 2026-04-01 with a primary completion date of 2026-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to investigate the clinical characteristics of pigmentary glaucoma and evaluate the efficacy and safety of ab-interno 120° trabeculotomy during the 6-month postoperative follow-up period.
Eligibility Criteria
Inclusion Criteria: * Meet the clinical diagnostic criteria for pigmentary glaucoma, with typical signs of pigment dispersion syndrome, extensive trabecular meshwork pigmentation, pathological intraocular pressure elevation, glaucomatous optic nerve damage, and characteristic visual field defects; * Underwent primary isolated ab-interno 120° trabeculotomy as the initial surgical treatment; * Have complete preoperative and postoperative examination data, including slit-lamp biomicroscopy, gonioscopy, intraocular pressure, visual field, and OCT RNFL measurements; * Able to complete regular follow-up for at least 6 months postoperatively. Exclusion Criteria: * Patients with exfoliation syndrome, exfoliative glaucoma, or other types of primary or secondary glaucoma; * Patients with a history of ocular trauma, intraocular surgery, uveitis, severe retinopathy, or other ocular diseases affecting intraocular pressure and visual function assessment; * Patients who underwent combined procedures such as concurrent cataract surgery or other anti-glaucoma surgeries during the operation; * Patients with severe systemic diseases, cognitive or psychiatric disorders that prevent cooperation with examinations and follow-up; * Patients with missing key clinical or follow-up data that preclude efficacy and prognosis evaluation.
Contact & Investigator
Wen Zeng, doctor
PRINCIPAL INVESTIGATOR
Zhongnan Hospital
Frequently Asked Questions
Who can join the NCT07713056 clinical trial?
This trial is open to participants of all sexes, aged 16 Years or older, up to 80 Years, studying Pigmentary Glaucoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07713056 currently recruiting?
Yes, NCT07713056 is actively recruiting participants. Contact the research team at Keminyk@163.com for enrollment information.
Where is the NCT07713056 trial being conducted?
This trial is being conducted at Wuhan, China.
Who is sponsoring the NCT07713056 clinical trial?
NCT07713056 is sponsored by Zhongnan Hospital. The principal investigator is Wen Zeng, doctor at Zhongnan Hospital. The trial plans to enroll 11 participants.